Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek January 9, 2006	Bio: Ginger L. Graham Throughout her life, Amylin Pharmaceuticals CEO Ginger Graham has demonstrated a theatrical flair and a persistence in the face of tough challenges.
The Motley Fool March 17, 2005 Stephen D. Simpson	Patience Rewarded at Last Amylin's battle to get Symlin approved was long and difficult, but success will have its rewards. Should investors take a shot?
The Motley Fool May 16, 2011 Brian Orelli	Diabetes Drug Duo Duels It Out in Court Amylin sticks up to partner Eli Lilly.
BusinessWeek December 22, 2003 Arlene Weintraub	Big Pharma Looks Beyond Insulin Researchers may be on the verge of major new treatments for diabetes and obesity.
The Motley Fool January 31, 2007 Brian Lawler	No Sickness for Amylin Sales of the drugmaker's type-2 diabetes drugs showed solid growth. Investors, take note.
The Motley Fool October 18, 2007 Brian Orelli	Amylin: Waiting on the Future Research and development costs drag down the drug developer's bottom line. Investors, take note.
The Motley Fool April 20, 2010 Brian Orelli	Drug Sales Down! Should We Celebrate? Amylin won't have completed results for a trial comparing Bydureon to Victoza until next year. But until that data is in, it might not be as easy to get the patients back as Amylin is making it out to be.
The Motley Fool January 27, 2011 Brian Orelli	Amylin Timeline Shortened -- Maybe Revenue down 6% year over year. Prescriptions of the company's top-selling drug, Byetta, down 5.9% quarter over quarter. Amylin Pharmaceuticals' fourth quarter wasn't pretty.
The Motley Fool October 2, 2007 Brian Orelli	Amylin's Bittersweet FDA News Diabetes drug moves ahead, but not as much as the company wanted. If the FDA rejection was due to safety issues, that wouldn't bode well for Amylin's plans to develop the active ingredient in SYMLIN as a weight-loss drug. Investors, take note.
The Motley Fool November 3, 2009 Brian Orelli	Amylin Scores a Hat Trick Amylin Pharmaceuticals got a triple dose of good news over the weekend.
The Motley Fool October 21, 2011 Brian Orelli	Full of News, but Worth a 15% Gain? Amylin serves up an appetizer.
The Motley Fool January 29, 2008 Brian Orelli	No Weight Loss at Amylin Bulging costs related to its diabetes drug Byetta keep the drugmaker from showing a profit this quarter.
The Motley Fool January 28, 2010 Brian Orelli	The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends.
The Motley Fool October 19, 2006 Brian Lawler	Amylin's One-Drug Wonder Unfortunately, with research and development costs growing to $54 million from $33 million last year, Amylin is still a few quarters away from profitability. Diabetes drug Byetta is set to boost Amylin's sales. Investors, take note.
The Motley Fool November 9, 2011 Brian Orelli	Byetta Breakup! Buying Opportunity? We all saw this coming. Amylin Pharmaceuticals and Eli Lilly decided staying together for the kids just wasn't worth it
The Motley Fool April 17, 2009 Brian Orelli	Cost-Cutting? Check. Increased Sales? Hmm ... Amylin has half the equation. Now it needs the other half.
The Motley Fool May 26, 2011 Brian Orelli	Amylin Scores First in Court But it is still early innings.
The Motley Fool July 22, 2008 Brian Orelli	Anemic Amylin's Signs of Recovery Sales of Amylin Pharmaceuticals' diabetes drug Byetta have slowed over the last few quarters, but the company seems to be turning things around.
The Motley Fool August 23, 2005 Stephen D. Simpson	A Cure for Amylin's Stock? Shares moved up after promising results from a diabetes-drug test. But will the gains last?
The Motley Fool March 27, 2009 Brian Orelli	The Skinny on a Triple-Decker Update Amylin's public relations department might need to go on a diet.
Chemistry World July 3, 2012 Andrew Turley	BMS and AstraZeneca buy Amylin for $7bn Pharma giants Bristol-Myers Squibb and AstraZeneca have teamed up to buy US biotech Amylin for $7 billion, further strengthening their position in the burgeoning market for diabetes drugs.
The Motley Fool September 22, 2010 Brian Orelli	Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown.
The Motley Fool May 31, 2011 Brian Orelli	Pay Attention, Biotech Investors Competitors and partners can't be ignored.
The Motley Fool April 22, 2008 Brian Orelli	Amylin Treads Water One-drug wonders like Amylin Pharmaceuticals can't get away with stagnant growth.
The Motley Fool November 30, 2007 Brian Orelli	Analyzing Amylin Amylin Pharmaceuticals holds its R&D day to update investors on the marketing strategy of its two diabetes products, as well as the development of its pipeline.
The Motley Fool July 22, 2009 Brian Orelli	The Blockbuster Around the Corner Amylin Pharmaceuticals' Byetta sales are improving, but is it enough?
The Motley Fool February 12, 2010 Brian Orelli	Don't Ignore This Potential Blockbuster Five trials later, Roche's diabetes drug taspoglutide seems like a winner.
The Motley Fool July 24, 2007 Brian Orelli	Is Amylin a Two-Hit Wonder? Two drugs, no profitability, but Amylin shares go up on future hopes after the pharmaceutical company reports.
The Motley Fool March 17, 2011 Brian Orelli	Taking a Bite Out of Amylin's Obesity Drug Potential Amylin Pharmaceuticals and Takeda announce they were putting a hold on the development of their obesity drug combination pramlintide/metreleptin due to safety issues.
The Motley Fool October 20, 2010 Brian Orelli	There Are No Safe Biotech Investments Amylin Pharmaceuticals and its partners, Eli Lilly and Alkermes, announced yesterday evening that the Food and Drug Administration had asked for more data before approving its once-weekly diabetes drug Bydureon.
The Motley Fool October 20, 2011 Travis Hoium	Amylin Pharmaceuticals Shares Jumped: What You Need to Know Shares of Amylin Pharmaceuticals jumped 11% today after the company released great earnings and pipeline news.
The Motley Fool June 16, 2010 Brian Orelli	A Drop on Bad News, but It Was a Long Shot Anyway Bydureon, Amylin Pharmaceuticals and Eli Lilly's once-weekly version of their twice-daily Byetta, has been beating up other diabetes drugs in a series of head-to-head clinical trials but it will have a tough time going after the monotherapy market.
The Motley Fool July 22, 2010 Brian Orelli	It's All About the Future for Amylin Its second quarter stank, but there's a lot up ahead.
The Motley Fool February 20, 2009 Brian Orelli	The Skinny on Diabetes Drugs The goal of diabetes drugs is to get the patient's blood glucose levels under control, but one class of drugs, called GLP1 agonists, have a nice side effect: weight loss. Which pharma companies can benefit?
The Motley Fool November 24, 2006 Brian Lawler	Amylin Gets Past the Formalities Following a formal approval from the EU for Byetta, Amylin can get down to business. Investors, take note.
The Motley Fool March 3, 2011 Brian D. Pacampara	Amylin Pharmaceuticals Shares Plunged: What You Need to Know Shares of Amylin Pharmaceuticals plummeted more than 20% Thursday after its type 2 diabetes drug Bydureon failed to meet primary endpoints in a 26-week study.
The Motley Fool April 16, 2010 Brian Orelli	It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet.
The Motley Fool September 30, 2011 Brian Orelli	A Drug Market That's 366 Million Strong Diabetes drugs have potential.
The Motley Fool March 31, 2009 Brian Orelli	Amylin Smacks Down the Competition Amylin's once-weekly blood sugar controlling drug Byetta trounces the competition.
The Motley Fool November 8, 2011 Tim Beyers	Amylin Pharmaceuticals Shares Plummeted: What You Need to Know Is this meaningful, or just another movement for Amylin Pharmaceuticals?
The Motley Fool March 3, 2011 Brian Orelli	Amylin Comes Up Snake Eyes Amylin Pharmaceuticals and partners Eli Lilly and Alkermes announced results of their head-to-head clinical trial comparing Bydureon with Novo Nordisk's diabetes drug Victoza.
The Motley Fool November 1, 2007 Brian Orelli	Good News From Amylin Isn't Good Enough Investors aren't impressed by Amylin's extended-release version of Byetta, worrying that the drug may be reaching market saturation.
The Motley Fool October 22, 2008 Brian Orelli	Why Amylin Skipped Some Byetta Numbers Usually the company presents the individual sales numbers for its two diabetes drugs from the year-ago quarter for investors to compare. But this time they were conspicuously absent.
The Motley Fool March 15, 2010 Brian Orelli	FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it.
The Motley Fool December 12, 2008 Brian Orelli	Amylin Gets Some FDA Love Amylin's once-weekly diabetes drug Byetta gets a green light from the FDA.
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
The Motley Fool June 11, 2008 Brian Orelli	Amylin's Down and Up on Diabetes Investors may be over-reacting to news both good and bad from Amylin Pharmaceuticals.
The Motley Fool December 7, 2007 Brian Orelli	Amylin's Temporarily Worthless Label Expansion Amylin releases label expansion data that won't be useful for a few years. Investors, take note.
The Motley Fool June 30, 2004 Alyce Lomax	A Monster Drug for Lilly? The drug giant files a new drug application (NDA) for its experimental new drug for diabetics.
The Motley Fool October 2, 2009 Brian Orelli	Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug.